Structure and function of axo-axonic inhibition
- Allen Institute for Brain Science, United States
- Princeton University, United States
- Baylor College of Medicine, United States
Abstract
Inhibitory neurons in mammalian cortex exhibit diverse physiological, morphological, molecular and connectivity signatures. While considerable work has measured the average connectivity of several interneuron classes, there remains a fundamental lack of understanding of the connectivity distribution of distinct inhibitory cell types with synaptic resolution, how it relates to properties of target cells and how it affects function. Here, we used large-scale electron microscopy and functional imaging to address these questions for chandelier cells in layer 2/3 of the mouse visual cortex. With dense reconstructions from electron microscopy, we mapped the complete chandelier input onto 153 pyramidal neurons. We found that synapse number is highly variable across the population and is correlated with several structural features of the target neuron. This variability in the number of axo-axonic ChC synapses is higher than the variability seen in perisomatic inhibition. Biophysical simulations show that the observed pattern of axo-axonic inhibition is particularly effective in controlling excitatory output when excitation and inhibition are co-active. Finally, we measured chandelier cell activity in awake animals using a cell-type specific calcium imaging approach and saw highly correlated activity across chandelier cells. In the same experiments, in vivo chandelier population activity correlated with pupil dilation, a proxy for arousal. Together these results suggest that chandelier cells provide a circuit-wide signal whose strength is adjusted relative to the properties of target neurons.
Data availability
Volume electron microscopy and segmentation data is available at https://www.microns-explorer.org/phase1. AIS synapse and PyC structural data are included in Supplemental Data. All other meshes and data tables are on Zenodo (DOI:10.5281/zenodo.5579388). All ChC calcium traces are also on Zenodo (DOI: 10.5281/zenodo.5725826). Analysis code and NEURON models are available at http://github.com/AllenInstitute/ChandelierL23.
Article and author information
Author details
Casey M Schneider-Mizell
Emmanouil Froudarakis
Funding
Intelligence Advanced Research Projects Agency (D16PC00003,D16PC00004,D16PC0005)
- Casey M Schneider-Mizell
- Agnes L Bodor
- Forrest Collman
- Derrick Brittain
- Adam Bleckert
- Sven Dorkenwald
- Nicholas L Turner
- Thomas Macrina
- Kisuk Lee
- Ran Lu
- Jingpeng Wu
- Jun Zhuang
- Anirban Nandi
- Brian Hu
- JoAnn Buchanan
- Marc M Takeno
- Russel Torres
- Gayathri Mahalingam
- Daniel J Bumbarger
- Yang Li
- Thomas Chartrand
- Nico Kemnitz
- William M Silversmith
- Dodam Ih
- Jonathan Zung
- Aleksandar Zlateski
- Ignacio Tartavull
- Sergiy Popovych
- William Wong
- Manuel Castro
- Chris S Jordan
- Emmanouil Froudarakis
- Lynne Becker
- Shelby Suckow
- Jacob Reimer
- Andreas S Tolias
- Costas A Anastassiou
- H Sebastian Seung
- R Clay Reid
- Nuno Maçarico da Costa
National Institute of Neurological Disorders and Stroke (U19 NS104648)
- H Sebastian Seung
Army Research Office (W911NF-12-1-0594)
- H Sebastian Seung
National Eye Institute (R01 EY027036)
- H Sebastian Seung
National Institute of Mental Health (U01 MH114824)
- H Sebastian Seung
National Institute of Neurological Disorders and Strokescience (R01 NS104926)
- H Sebastian Seung
National Institute of Mental Health (RF1MH117815)
- H Sebastian Seung
Mathers Foundation
- H Sebastian Seung
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Disclaimer: The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of IARPA, DoI/IBC, or the U.S. Government.
Ethics
Animal experimentation: All animal procedures were approved by the Institutional Animal Care and Use Committee at the Allen Institute for Brain Science (1503 and 1804) or Baylor College of Medicine (AN-4703).
Copyright
© 2021, Schneider-Mizell et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,954
- views
-
- 712
- downloads
-
- 66
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Structure and function of axo-axonic inhibition
eLife 10:e73783.
https://doi.org/10.7554/eLife.73783
Further reading
-
- Neuroscience
Motivation depends on dopamine, but might be modulated by acetylcholine which influences dopamine release in the striatum, and amplifies motivation in animal studies. A corresponding effect in humans would be important clinically, since anticholinergic drugs are frequently used in Parkinson’s disease, a condition that can also disrupt motivation. Reward and dopamine make us more ready to respond, as indexed by reaction times (RT), and move faster, sometimes termed vigour. These effects may be controlled by preparatory processes that can be tracked using electroencephalography (EEG). We measured vigour in a placebo-controlled, double-blinded study of trihexyphenidyl (THP), a muscarinic antagonist, with an incentivised eye movement task and EEG. Participants responded faster and with greater vigour when incentives were high, but THP blunted these motivational effects, suggesting that muscarinic receptors facilitate invigoration by reward. Preparatory EEG build-up (contingent negative variation [CNV]) was strengthened by high incentives and by muscarinic blockade, although THP reduced the incentive effect. The amplitude of preparatory activity predicted both vigour and RT, although over distinct scalp regions; frontal activity predicted vigour, whereas a larger, earlier, central component predicted RT. The incentivisation of RT was partly mediated by the CNV, though vigour was not. Moreover, the CNV mediated the drug’s effect on dampening incentives, suggesting that muscarinic receptors underlie the motivational influence on this preparatory activity. Taken together, these findings show that a muscarinic blocker impairs motivated action in healthy people, and that medial frontal preparatory neural activity mediates this for RT.
-
- Medicine
- Neuroscience
The advent of midazolam holds profound implications for modern clinical practice. The hypnotic and sedative effects of midazolam afford it broad clinical applicability. However, the specific mechanisms underlying the modulation of altered consciousness by midazolam remain elusive. Herein, using pharmacology, optogenetics, chemogenetics, fiber photometry, and gene knockdown, this in vivo research revealed the role of locus coeruleus (LC)-ventrolateral preoptic nucleus noradrenergic neural circuit in regulating midazolam-induced altered consciousness. This effect was mediated by α1 adrenergic receptors. Moreover, gamma-aminobutyric acid receptor type A (GABAA-R) represents a mechanistically crucial binding site in the LC for midazolam. These findings will provide novel insights into the neural circuit mechanisms underlying the recovery of consciousness after midazolam administration and will help guide the timing of clinical dosing and propose effective intervention targets for timely recovery from midazolam-induced loss of consciousness.
